Former Chief Financial Officer · Xenon Pharmaceuticals Inc. (XENE)

Sherry Aulin

FY2025 is the first fiscal year CompBrief holds for Sherry Aulin as a named executive officer of Xenon Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$356,453

Compensation figures as of the proxy filed April 22, 2026 (DEF 14A).

Sherry Aulin compensation by year

Xenon Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as Xenon Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$330,441
Bonus$1,539
Stock awards$0
Option awards$0
Non-equity incentive$0
Pension and deferred compensation$0
All other$24,473
Total$356,453

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Xenon Pharmaceuticals Inc. DEF 14A filed April 22, 2026, accession 0001193125-26-170320, and prior-year filings. Open the filing on EDGAR.

Xenon Pharmaceuticals’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Ian MortimerPresident and Chief Executive Officer$9,221,712
Thomas KellyChief Financial Officer$7,238,664
Darren ClineChief Commercial Officer$4,048,214
Christopher KenneyChief Medical Officer$3,145,290
Andrea DiFabioChief Legal Officer and Corporate Secretary$3,062,790
Sherry Aulin · this pageFormer Chief Financial Officer$356,453

The full Xenon Pharmaceuticals compensation record

free company brief

This page is one person within Xenon Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Xenon Pharmaceuticals's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Xenon Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy